Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

The Daily Biotech Pulse: Merck's Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug

Benzinga.com  April 12, 2019

The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering

Benzinga.com  April 10, 2019

Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing

Business Wire April 9, 2019

SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference

Business Wire April 8, 2019

Revance to Participate in the Needham Healthcare Conference

Business Wire April 2, 2019

Revance to Participate in Upcoming Investor Conferences

Business Wire March 5, 2019

Revance Releases Fourth Quarter and Full Year 2018 Results

Business Wire February 26, 2019

Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

Business Wire February 12, 2019

Revance Announces Closing of Public Offering of Common Stock

Business Wire January 22, 2019

22 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  January 17, 2019

Revance Announces Pricing of Public Offering of Common Stock

Business Wire January 17, 2019

The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

Benzinga.com  January 16, 2019

10 Stocks To Watch For January 16, 2019

Benzinga.com  January 16, 2019

8 Stocks Moving In Tuesday's After-Hours Session

Benzinga.com  January 15, 2019

Revance Announces Proposed Public Offering of Common Stock

Business Wire January 15, 2019

Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference

Business Wire January 15, 2019

Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones

Business Wire January 7, 2019

Revance Announces China Market License Agreement with Fosun Pharma for RT002

Business Wire December 4, 2018

Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program

Business Wire December 4, 2018

Market Trends Toward New Normal in Palatin Technologies, Revance Therapeutics, Geo Group, QUANTENNA COMMS, The Navigators Group, and INVESCO MORTGAGE CAPITAL INC — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire November 27, 2018